MLAB

LAKEWOOD, Colo. (AP) — LAKEWOOD, Colo. (AP) — Mesa Laboratories Inc. (MLAB) on Wednesday reported a loss of $4.1 million in its fiscal fourth quarter. On a per-share basis, the Lakewood, Colorado-based company said it had a loss of 75 cents. Earnings, adjusted for non-recurring costs and stock option expense, came to $2.76 per share. The quality control instruments and disposable products maker posted revenue of $63.7 million in the period. For the year, the company reported profit of $6.7 million, or $1.21 per share. Revenue was reported as $249.1 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MLAB at https://www.zacks.com/ap/MLAB

LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q26”) and fiscal year (“FY26”) ended March 31, 2026 (amounts in thousands). 4Q26 Financial Summary – (comparisons are versus the same prior year period) Revenues increased 2.6% Non-GAAP organic and core organic revenues1 growth was 2.6% and (0.6)%, respectively Operating income increased 87% to $2,748 Non-GAAP adjusted operating income (“AOI”) excluding unusual items2 increased 49.2% and was 28.7% as a percentage of revenues Repaid $14,700 of debt and reduced Total Net Leverage Ratio3 to 2.11 Full FY26 Financial Summary – (comparisons are versus the prior fiscal year) Revenues increased 3.4% Non-GAAP organic and core organic revenues growth was 3.4% and 1.2%, respectively Operating income increased 13.3% to $18,511 Non-GAAP adjusted operating income excluding unusual items increased 11.9% and was 25.5% as a percentage of revenues We operate a diversified business across four divisions: Sterilization and Disinfection Control (“SDC”), Biopharmaceutical Development (“BPD”), Calibration Solutions (“CS”), and Clinical Genomics (“CG”). Executive Commentary (amounts in thousands) “As announced in March, I am in the middle of my onboarding journey as I am conducting my first 100 days review of the businesses since joining Mesa on April 13. I want to share that I am even more excited today than the day I joined. The Mesa diversified platform has tremendous potential to create shareholder value while delivering on our promise to Protect the Vulnerable. Upon completion of my 100-day review of our business, I am looking forward to begin meeting with our shareholders and discussing my vision for the Company moving forward. I also expect to be in position to provide rest of the year guidance along with the release of H1 results,” said Siddhartha Kadia, President and CEO of Mesa. “We delivered 2.6% organic (-0.6% core organic) revenues growth in 4Q26 resulting from significant growth in SDC, which was aided by a reduction in backlog to more normalized levels, a less volatile quarter in CG and a positive impact from FX. This strong growth was mostly offset by a significant decline in BPD revenues, d...

LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 2026 at approximately 6:00 A.M. Eastern Time (ET) on Wednesday, May 27, 2026. About Mesa Laboratories Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Mesa Laboratories Contacts Siddhartha Kadia, President and CEO John Sakys, Vice President and CFO 1-303-987-8000 For more information about Mesa Laboratories, please visit our website at www.mesalabs.com.

LAKEWOOD, Colo., April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Forward Looking Statements This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2025, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q a...

LAKEWOOD, Colo. (AP) — LAKEWOOD, Colo. (AP) — Mesa Laboratories Inc. (MLAB) on Tuesday reported earnings of $3.6 million in its fiscal third quarter. The Lakewood, Colorado-based company said it had net income of 65 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, were $3.07 per share. The quality control instruments and disposable products maker posted revenue of $65.1 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MLAB at https://www.zacks.com/ap/MLAB

LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q26”) ended December 31, 2025 (amounts in thousands). 3Q26 Financial Summary – (comparisons are versus the same year ago period Revenues increased 3.6% Non-GAAP organic and core organic revenues1 growth was 3.6% and 1.2%, respectively Non-GAAP organic revenues growth excluding CG China revenues (entirely diagnostics) was 5.7% Operating income increased 38.0% to $7,975 Non-GAAP adjusted operating income (“AOI”) excluding unusual items2 increased 15.4% and was 26.2% as a percentage of revenues Repaid $8.7 million of debt and reduced Total Net Leverage Ratio3 to 2.62 We operate a diversified business across four divisions: Sterilization and Disinfection Control (“SDC”), Biopharmaceutical Development (“BPD”), Calibration Solutions (“CS”), and Clinical Genomics (“CG”). Executive Commentary (amounts in thousands) “Steady execution and relatively stable markets across Europe and North America helped deliver 3.6% organic (1.2% core organic) revenues growth in 3Q26 versus the prior year, or 5.7% when excluding CG China revenues. Total company growth was 7.2% sequentially, well within our expected growth range. Strong growth in BPD, continued growth in CG excluding China, and a recovery towards normal SDC deliveries overcame strong but expected headwinds in CG China. For the first nine months of FY26, we delivered 3.7% organic revenues growth, but 6.6% when excluding CG China revenues. With continued strong execution across the business and less impactful CG China compares moving forward, we expect our positive momentum to continue in 4Q26” said Gary Owens, Chief Executive Officer of Mesa. “Profitability for the quarter, using our preferred metric of AOI excluding unusual items as a percentage of revenues, was very robust at 26.2% versus 23.5% for both 3Q25 and the whole of FY25. We expect this margin rate to moderate slightly over the next several quarters as we fully realize the benefits from our cost realignment actions at the end of 2Q26 while continuing to increase investment in SDC into the first half of FY27. In the quarter, improving volumes, favorable product mix, and benefits from th...

LAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Forward Looking Statements This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2025, as well as other risks and uncertainties detailed from time to time in our reports on Forms 1...

LAKEWOOD, Colo., Dec. 03, 2025 (GLOBE NEWSWIRE) -- - Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern Time (ET) on Tuesday, February 3, 2026. About Mesa Laboratories Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Mesa Laboratories Contacts Gary Owens, President and CEO John Sakys, CFO 1-303-987-8000 For more information about Mesa Laboratories, please visit our website at www.mesalabs.com.

LAKEWOOD, Colo. (AP) — LAKEWOOD, Colo. (AP) — Mesa Laboratories Inc. (MLAB) on Thursday reported net income of $2.5 million in its fiscal second quarter. On a per-share basis, the Lakewood, Colorado-based company said it had net income of 45 cents. Earnings, adjusted for amortization costs and stock option expense, were $1.76 per share. The quality control instruments and disposable products maker posted revenue of $60.7 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MLAB at https://www.zacks.com/ap/MLAB

LAKEWOOD, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q26”) ended September 30, 2025 (amounts in thousands). Financial Summary – 2Q26 versus the same year ago period Revenues increased 5.0% Non-GAAP core organic revenues1 growth was 3.7% Operating income increased 34.7% to $4,724 Non-GAAP adjusted operating income (“AOI”) excluding unusual items2 increased 6.1% and was 25.1% as a percentage of revenues We operate a diversified business across four divisions: Sterilization and Disinfection Control (“SDC”), Biopharmaceutical Development (“BPD”), Calibration Solutions (“CS”), and Clinical Genomics (“CG”). Executive Commentary (amounts in thousands) “Solid execution and market stability across Europe and North America helped deliver 5.0% organic (3.7% core organic) revenue growth in 2Q26 versus the prior year. BPD growth, aided by delayed bookings from 1Q26, continued strength in CS, and double-digit growth in CG excluding China overcame softness in SDC deliveries and strong but expected headwinds in CG China (58% decrease versus prior year). Despite macroeconomic uncertainty, we delivered strong growth of 3.7% organic over the first half of FY26, and we expect revenues to sequentially increase in 3Q26,” said Gary Owens, Chief Executive Officer of Mesa. “Profitability for the quarter, using our preferred metric of AOI excluding unusual items as a percentage of revenues, was strong at 25.1% versus 24.8% in 2Q25 and 23.5% for the whole of FY25. Quarterly performance was impacted by headwinds of 40 bps from tariffs and 60 bps from FX. During the quarter, we significantly reduced our cost structure to align with the new reality of global tariffs, a weaker dollar, and continuing headwinds in the CG China diagnostics market while also accelerating investments in our highest growth opportunities. We reduced annualized costs by $3.2M including reductions of $2.1M in CG which will begin to be realized in 3Q25. Starting in 3Q25 and into the first half of FY27, we plan to reinvest approximately $0.9M of these savings into SDC to fuel that Division’s long-term growth. Together, these actions are expected to generate $2.3M of net annualized cost saving...

Lakewood, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Forward Looking Statements This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2025, as well as other risks and uncertainties detailed from time to time in our reports on Form...

LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market close on Thursday, November 6, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. CONTACT: Gary Owens, President and CEO, or John Sakys, CFO, both of Mesa Laboratories, Inc., +1-303-987-8000 For more information about the Mesa, please visit our website at www.mesalabs.com.